Targeted therapies in breast cancer: New challenges to fight against resistance

Table 3 Some of the current clinical trials in breast cancer targeted therapy (http://www.breastcancertrials.org)

Title of clinical trial	Type of cancer
Randomized open label Phase II trial: Kadcyla, tykerb and abraxane vs herceptin, tykerb and taxol before Surgery for HER2+ tumors NCT02073487	HER2+
Phase III randomised, placebo controlled clinical trial: Chemotherapy and a PARP-inhibitor for BRCA1/2+, HER2- advanced breast cancer NCTO2163694	HER2-, BRCA1/2+ metastatic or locally advanced unresectable breast cancer
Phase II, multicenter, randomized clinical trial: Alisertib with taxol for advanced ER+/HER2- or TNBC NCTO2187991	ER+/HER2- TNBC
Phase II Clinical trial: Gemzar, herceptin and perjeta for HER2+ metastatic breast cancer NCTO2252887	HER2+ metastatic breast cancer
Phase I clinical trial: CD-839 for advanced breast tumors NCTO2071862	Advanced breast cancer and solid tumors
Phase I clinical trial: Saracatinib and anastrozole for ER-positive disease NCTO1216176	ER+
Randomised Phase III clinical trial: Hormone therapy with or without ibrance for HR+, HER2- stage II-III breast cancer NCTO2513394	HR+, HER2-
Phase II clinical trial: CDK-inhibitor for previously treated metastatic disease NCTO1037790	Previously treated metastatic breast cancer
Phase I clinical trial: GS-5745 in metastatic HER2- breast cancer and other solid tumors NCTO1813282	Metastatic HER2- breast cancer not responding to other treatments